Overview: FISH 14q32-3 IGH Panel
Introduction: The FISH 14q32-3 IGH Panel is a diagnostic tool designed to detect IGH gene rearrangements using whole blood or bone marrow samples. In India, IGH translocations (e.g., t(14;18) in follicular lymphoma, t(14;16) in multiple myeloma) occur in ~10-20 percent of B-cell malignancies, guiding prognosis and targeted therapy (e.g., bortezomib in myeloma with IGH abnormalities). High morbidity from under-testing in rural/low-SES hematology patients, limited FISH access, delayed risk-adapted treatment leading to progression. Per cytogenetics practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs FISH for IGH breakapart over 1-2 days with high sensitivity/specificity, valuable for molecular subtyping in lymphoma/myeloma. This diagnostic falls under genetic cancer screening and targets patients with B-cell malignancies, addressing accurate detection to guide therapy and prognosis. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise genetic classification and improving outcomes. Its blood/bone marrow-based approach ensures reliable rearrangement detection.
Other Names: FISH IGH Pnl.
FDA Status: FDA approved, CLIA certified for cytogenetics, compliant with 2025 standards.
Historical Milestone: IGH FISH standard; in India, used in lymphoma/myeloma protocols.
Purpose: The test detects 2 parameters including IGH gene breakapart to guide genetic assessment, identify translocations, inform therapy/prognosis.
Test Parameters: 1. IGH Gene Breakapart, 2. Chromosomal Rearrangement.
Pretest Condition: No fasting required; patients should have confirmed B-cell malignancy.
Specimen: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for FISH).
Medical History: Patients should provide details on malignancy subtype, stage, prior therapy.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected IGH rearrangement including poor prognosis, benefits of detection, and minimal discomfort from blood/bone marrow draw.
Procedural Considerations: The test involves sample processing using FISH by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided probes/controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low tumor burden can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive IGH rearrangement indicates specific subtype, necessitating specialist input. Negative may require follow-up.
Specialist Consultation: Hematologists/oncologists should be consulted for management.
Additional Supporting Tests: Karyotype, NGS for confirmation.
Test Limitations: Detects rearrangement only; comprehensive approach required.
References: Indian Journal of Hematology 2024, Lymphoma Studies India 2023.
